ISI: OR: 0.50, 95%CI: 0.360.68, P = 1.00 10 5
As dual agonists gain traction, its exciting to see real-world evidence catching up with clinical promise and reinforcing the value of going beyond GLP-1
2.2 Imminent generics entry Semaglutide, the biggest blockbuster product in the GLP-1 market today, is expected to lose patent protection in China in 2026, earlier than in most developed markets
Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis
Responsible play toolsdeposit caps, timeout options, and reality checksshould be easy to find and adjust
Clinical trials evaluate medications through different types of endpoints